Phase II trial of neoadjuvant mFOLFOX 6 with panitumumab (P) in T3 rectal cancer with clear mesorectal fascia (MRF) and <i>KRAS</i>, <i>NRAS</i>, <i>BRAF</i>, <i>PI3KCA</i> wild type (4WT). GEMCAD 1601 PIER trial.

Carlos Fernández-Martos, Carles Pericay, Joan Maurel et al.|Journal of Clinical Oncology|2021

Cited by 3